Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avita Therapeutics

1.105
-0.015-1.34%
Volume:1.01M
Turnover:1.12M
Market Cap:168.47M
PE:-0.05
High:1.140
Open:1.130
Low:1.075
Close:1.120
52wk High:4.520
52wk Low:1.060
Shares:152.47M
Float Shares:5.34M
Volume Ratio:1.54
T/O Rate:18.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-22.182
EPS(LYR):-29.251
ROE:-1746.27%
ROA:-36.33%
PB:-16.52
PE(LYR):-0.04

Loading ...

Company Profile

Company Name:
Avita Therapeutics
Exchange:
ASX
Establishment Date:
- -
Employees:
260
Office Location:
28159 Avenue Stanford,Suite 220,Valencia,California,United States
Zip Code:
91355
Fax:
661 749 9430
Introduction:
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.